MedicuRx Corporation

MR-01 Product Summary

Confidential Presentation

November 2014

Executive Summary

MedicuRx Corporation (MedicuRx) is a party to an

exclusive letter of intent (“LOI”) with Arno Therapeutics Inc.

(“Arno”) related to the license of MR-01, a novel third-

generation Camptothecin analogue, under development for

the treatment of Glioblastoma Multiforme (GBM)

MR-01 has completed two phase 1 studies and has

demonstrated proof of concept in a XX patient Phase II

study

Dr. Joseph Rubinfeld, Ph.D, founder of MedicuRx,

recognized the unique ability of MR01 to ….. And has

assembled a team complete any necessary … to reach

Phase 3 and ultimate approval of the drug by the FDA

CONFIDENTIAL

Overview of Camptothecins

Camptothecins are Topoisomerase-I inhibitors that cause single strand DNA breaks

First generation: clinically unsuccessful

Demonstrated excellent preclinical efficacy, but poor in vivo stability and

significant toxicity

Second-generation analogues: clinically successful

Third-generation analogues: focused on improving lactone stability and regulating plasma protein binding

The two approved Camptothecin analogues on the market recorded $900 million in aggregate revenue in 2008

Hycamtin® (topotecan), Camptosar® (irinotecan)

CONFIDENTIAL

MR-01

MR-01 is a small molecule, rationally designed to improve lactone stability by increasing lipophilicity

Increased lipophilicity may increase central nervous system

penetration

Potential for more predictable metabolism/toxicity

May cross blood brain barrier

Phase I study demonstrated that ~ 85% remains in active “lactone” form

Phase I data, presented at ASCO 2009, demonstrated anti-

tumor activity, safety and desired PK profile

Phase II trial enrollment completed with patients with GBM and Gliosarcoma (GSC)

CONFIDENTIAL

Silatecans Provide Enhanced Stability

Enhanced lipophilicity promotes drug partitioning into lipid

bilayers, which prevents hydrolysis in the aqueous milieu of

blood, favoring the lactone form

Interference with the binding of the drug carboxylate to

human serum albumin (10-OH functionality)

Best candidate, MR-01, received NIH’s Rapid Access to

Intervention Development (RAID) program support in three

funding cycles

CONFIDENTIAL

Silatecans Provide Enhanced Stability

CONFIDENTIAL

Lactone Carboxylate

pH < 7 pH >7

Glioblastoma Multiforme (GBM)

Most common & deadliest of malignant primary brain tumors

Classified as a grade iv (most serious) astrocytoma

Develops primarily in the cerebral hemispheres

Develops from the lineage of star-shaped glial cells called astrocytes that support nerve cells; may also develop in other parts of the brain, brainstem, or spinal cord

Incidence - approximately 23,000 patients diagnosed per year; survival rate - approximately 12-15 months from diagnosis, only 3-5% survive 3+ years

Limited treatment options, with limited success

Aggressive surgery; radiation therapy; chemotherapy

CONFIDENTIAL

Phase II Study: Glioblastoma

Multiforme/Gliosarcoma

A Phase II Study of MR-01 in Adult Patients with Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma (GSM)

Study Design: Phase II single agent 7.5 mg/m2 i.v. (1 hour infusion) once daily for 5 days on an every 21-day cycle

Cohort : Avastin® naïve and Avastin® Relapse (>90 days after last dose)

Primary Endpoint: 6 month Progression Free Survival (PFS)

Results: 6 patients have achieved the 6 month PFS

Premise on “Futility Analysis” : If ≥ 4/32 patients achieve the PFS

endpoint then MR-01 would be worthy of further evaluation

Statistically Significant Results at 6 patients/32 achieving Primary Endpoint AND 2 more patients responded beyond Futility Analysis

CONFIDENTIAL

Phase II Study in GBM/GSM

Study design: Single agent MR-01 given 7.5 mg/m2,

IV QDx5/21 days to patients with recurrent

Avastin® naïve and Avastin® responders

If received Avastin relapsed >90 days (N=32)

Study Endpoint:

6 month PFS in 20% of patients on trial or total of

6 patients, which is considered statistically significant

Unmet medical need due to limited treatment options

PI: James Vrendenburgh, M.D., was at Duke University, now at Saint Francis Hospital and Medical Center in Hartford, CT

(Seven sites in the US and Canada)

CONFIDENTIAL

Phase II Glioblastoma Multiforme/Gliosarcoma Summary

Phase II Study Overview

32 patients enrolled @ 7 US sites

32 Avastin® naïve/relapse patients

First patient first dose 15DEC 09

Last patient first dose 21FEB12

Primary efficacy endpoint for the Avastin® Naïve/relapse cohort is 6-month PFS

6 patients have reached the primary endpoint

The highest number of cycles of treatment received:

39 cycles or approximately 27 months on treatment with high Quality of Life (QOL)

CONFIDENTIAL

Clinical Update – Fully Enrolled

-------

5 I

I

Summary Avastin® Naïve/Relapse # Dosed 32 # Dose Reductions 3 # SAEs 4 # Subjects > 39 cycles 1 # Subjects > 16 cycles 2 # Subjects > 10 cycles 3 # Subjects > 9 cycles 6 # Subjects > 6 cycles 7 # Subjects > 4 cycles 10 # Subjects > 3 cycles 10 # Subjects > 2 cycles 23 # Subjects > 1 cycle 32

CONFIDENTIAL

Summary MR-01

A Novel Third-Generation Camptothecin Analogue

Topoisomerase-1 Inhibitor, which cause Single Strand DNA Breaks

Improved Bioavailability due to Increased Stability in Blood

No Evidence of Significant Toxicity (severe diarrhea), in Contrast to other Camptothecins

In Late Phase II Clinical Trial with Evidence of Reaching Primary Efficacy Endpoint of Progression Free Survival (PFS) of Greater than 6 months

In Late Phase II Clinical Trial in GBM patients with evidence of Disease and Tumor Regression

Other Potential Indications are in Small-Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and MDS

CONFIDENTIAL

CMC Summary

API

GMP I “ Standard route “ using 10- hydroxy- camptothecin as starting material

Process developed at US based CRO

Stability: Stable for at least 60 months @ 25C°/60%RH

Exploratory route (fully synthetic)

Avoids the use of cytotoxic starting material

Only final step will required cytotoxic suite

Likely potential for various patents ranging from composition of matter, process, intermediates, etc.

Avoids high cost ‘camptothecin backbone’ starting materials

Route developed at China based CRO

Will require process development/optimization

and scale-up

CONFIDENTIAL

CMC Summary

Drug Product

cGMP I – III:

Simple solution 10mg/vial ( 5mg/ml)

cGMP I, II manufactured by NCI

cGMP III manufactured by Arno Therapeutics

No major foreseeable scale-up challenges

Very stable DP: Current retest date: > 60 months at 25°C/60% RH

Lyophilized cyclodextrin formulation ( IP with U of Kentucky until 2022 - under discussions with Arno on development)

Prototype demo batch ( 5L scale)

Stable for at least 24 months at 25°C/65% RH

CONFIDENTIAL

Patent Summary

Global

Composition of matter expired in June 2013 (Univ. of Pittsburg-Licensor)

Positive Outcome: 1) 20% licensor’s fee-no longer applicable, 2) 5% sales royalty fees-no longer applicable

Cyclodextrin formulation patent valid until 2022

No practical relevance

Analog patents still valid

No practical relevance

Intermediate patent still valid

Relevance depends on synthesis route

CONFIDENTIAL

Patent Summary Global Patent review and patent strategy:

10- hydroxy- camptothecin starting material derived from natural product, a native Chinese desiduous tree, Camptotheca acuminata

Camptotheca acuminata has seasonal, variable and availability challenges

New Synthetic route developed: Higher Reference Standards (No Further Toxicology Studies

needed)

Far Less Contaminants

No Variability

No Seasonal and Availability of 10- hydroxy- camptothecin starting material challenges

No Cytotoxic Starting Material needed

Developing Scale-up and Optimization process

Patent Strategy Filings: 1) Composition of Matter/Active

Pharmaceutical Product (API), 2) Intermediates, 3) Synthetic Route 4) Active Drug Product

CONFIDENTIAL

Temodar®- Temozolomide, Orally Active Alkylating Agent (Schering-Plough now Merck)

oApproved in 2005 for Newly Diagnosed Adult Patients

oPatent expired August 2013 (Teva and Perrigo now have approved Generics)

oAnnual sales-Estimated $882 Million Globally, Year 2012

Avastin®- Bevacizumab, Antiangiogenic VEGF Inhibitor (Genentech/Roche)

o Approved in 2009 for Patients with Recurrent GBM

and Prior Treatment

o Annual sales-Estimated $170 Million Globally for this

Indication, Year 2012

GBM Approved Drugs

CONFIDENTIAL

MR-01 Potential Market Revenue

Two Approved Camptothecin Analogues:

Hycamtin®-Topotecan, Semi-Synthetic Derivative (GlaxoSmithKline) o Approved in 2007 for Small Cell Lung Cancer & Ovarian

o Annual Sales World Wide Approximately $500Million

Camptosar®-Irinotecan, Semi-Synthetic Derivative (Pfizer) o Approved in 1996 for Metastatic Colorectal Cancer

o Annual Sales World Wide Approximately $1Billion

o Generics available through ACCORD Healthcare, Actavis, etc.

CONFIDENTIAL

MR-01 Milestones & Timelines

Milestones: Phase IIb/III ready Compound in GBM

Statistically Significant Results with 6 Patients out of 32 who Achieved Primary End-Point: 6 Month Progression Free Survival

Significantly Improved QoL for Patients on MR-01 and Tumor Shrinkage

Selection of Manufacturing Process and Contract Manufacturing Facilities

Estimated Timelines to Completion based on Assumptions (For Phase IIb through End of Phase III):

Acquisition of MR-01: Target date no later than November 2014

Phase IIb/III Meeting with FDA: February 2014

KOL Meeting: March 2015

Final Design and Approval of Protocol: May 2015

First Patient Screened and Enrolled: August 2015

Last Patient Responder on 6-Month PFS (Assumption based 12 Patients in PIIb and 150 Patients in PIII): May 2019

CONFIDENTIAL

Executive Management

Joseph Rubinfeld, Ph.D.: Co-Founder & CEO

Dr. Rubinfeld co-founded SuperGen, Inc. (NASDAQ:ASTX) in 1991, and served as Chief Executive Officer, President and Director until 2005. During his tenure, Dr. Rubinfeld guided and established SuperGen into an internationally recognized pharmaceutical company with successful oncology products including Nipent® (which surpassed $20 million), Mitozytrex, Mitomycin, Daunorubicin, and the Surface Safe® disposable cleaning system. He attained FDA approval for Dacogen® (Decitabine) in May 2006 for myelodysplastic syndrome (MDS). In 2005, Dr. Rubinfeld founded a new company, JJ Pharma, Inc., of which he was Chairman and Chief Executive Officer – JJ Pharma’s primary interest is cardiovascular research. Dr. Rubinfeld was one of the four initial founders (1980) of Amgen, Inc. (AMGN:NASDAQ), and served as Vice President and Chief of Operations until 1983. Dr. Rubinfeld received a Ph.D. in chemistry from Columbia University and holds nearly 100 patents. He is credited with inventing amoxicillin, biodegradable detergents and shortening the Polaroid film development process to 10 seconds. He was also a founding father of the Industrial Biotechnology Association (IBA), which was the parent of BIO. From 1987 to 1990, he was a Senior Director at Cletus Corporation. From 1968 to 1980, Dr. Rubinfeld was employed by Bristol-Myers Company International Division in a variety of positions, including Vice President and Director of Research and Development. At Bristol-Myers, Dr. Rubinfeld was instrumental in developing and licensing its initial oncologic product lines, Mitomycin, Etoposide, Cisplatin, and Bleomycin. He was also responsible for the development of two major antibiotics, amoxicillin and Cephadroxil. Dr. Rubinfeld is on the Board of Directors and Scientific Advisory Board member of CytRx, Inc., Amarantus Biosciences, Regenicin, Inc., and Generex Corporation. Dr. Rubinfeld received the Common Wealth Award for Invention for his discovery of biodegradable detergents.

20 CONFIDENTIAL

Executive Management

Mark J. Gustavson – Co-Founder, Chairman & CFO

Mark J. Gustavson, based in our San Francisco office, is a seasoned and accomplished banker with a depth of experience in institutional backed plays and international business. Mark has held many simultaneous roles including Angel Investor, early stage fund raiser, reorganization specialist and company founder, acquiring experience on “‘both sides of the street.” Mr. Gustavson 's general management and operations background in banking complements his focus on strategic investment banking work at Colmen Group, tailoring solutions to each client’s unique needs. Sell Side Private Equity Representation yielded significant results, from seed round funding, Series A and bridge financing to successful exits through the IPO stage and beyond. Sector specialties include BioPharma, fiber optics, IP-based banking, mobile device systems, IP-based payment technologies, and social media. Prior to Colmen, Mark was a Private Banker at Hong Kong and Shanghai Banking Corporation (HSBC) in Saipan, Commonwealth of the Northern Mariana Islands. While at HSBC, Mr. Gustavson performed Portfolio and Global Investment Management, employing his extensive knowledge of early stage technology companies to domestic investors. Mr. Gustavson has also testified as an expert witness on banking laws and federal statutory and regulatory guidelines regarding current and ongoing litigation within the CNMI, and consulted with U.S. Senate legal counsel on pending CNMI banking legislation. Mr. Gustavson holds a BS degree in Political Science from the University of Oregon.

21 CONFIDENTIAL